Pacira BioSciences, Inc. (PCRX) Stock Forecast & Price Target
Pacira BioSciences, Inc. · NASDAQ
$26.83+0.36 (+1.36%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 5 firms covering Pacira BioSciences, Inc, 3 rate it Buy or better, 2 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $24.00 to $38.00, a moderate spread. The average target of $29.40 sits 10% above the current $26.83. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.76 next quarter toward $3.65 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 ratings
Moderate Buy
Strong Buy00%
Buy360%
Hold240%
Sell00%
Strong Sell00%
Based on 5 analysts giving stock ratings to Pacira BioSciences, Inc.
As of Jul, 3 of 5 firms rate PCRX a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
PCRX EPS & revenue forecast
EPS · NEXT QUARTER
$0.76
Range $0.64 – $0.87 · 6 analysts · +8% YoY
Next period, 6 analysts expect Pacira BioSciences, Inc. to earn $0.76 a share (range $0.64 – $0.87), versus $0.70 a year earlier. Full-year consensus is $2.88, growing to $3.65 the year after.
REVENUE · NEXT QUARTER
$190.6M
Range $188.8M – $192.5M · 6 analysts · +6% YoY
Revenue is expected to reach $190.6M (range $188.8M – $192.5M), +6.2% year-over-year. Full-year consensus is $767.8M, rising to $831.3M next year.
Top analysts covering Pacira BioSciences, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PCRX.
#1
Serge Belanger
Needham · Rank #83
Buy
$32.00+19.3% to target
Overall win rate
48%
+ Follow
#2
Oren Livnat
HC Wainwright & Co. · Rank #142
Buy
$65.00+142.3% to target
Overall win rate
54%
+ Follow
#3
Balaji Prasad
Barclays · Rank #147
Buy
$24.00-10.5% to target
Overall win rate
44%
+ Follow
#4
Gregory Renza
RBC Capital · Rank #179
Hold
$18.00-32.9% to target
Overall win rate
34%
+ Follow
#5
Douglas Tsao
HC Wainwright & Co. · Rank #212
Buy
$38.00+41.6% to target
Overall win rate
35%
+ Follow
PCRX stock forecast FAQ
What is PCRX's average 12-month price target?+
The 5 analysts with a live target average $29.40 for Pacira BioSciences, Inc. over the next 12 months, ranging from a $38.00 high to a $24.00 low.
Is PCRX stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 5 analyst ratings, 3 are Buy or Strong Buy, 2 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for PCRX?+
The Street-high target is $38.00 (HC Wainwright & Co.), and the Street-low is $24.00 (RBC Capital). The average of all 5 active targets is $29.40.
How many Wall Street analysts cover PCRX?+
5 analysts have an active rating on Pacira BioSciences, Inc., and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering PCRX?+
Among analysts who currently cover PCRX, Serge Belanger of Needham has the strongest overall Quantellect track record (Rank #83). Their current call is Buy with a $32.00 target.
What is Pacira BioSciences, Inc.'s projected EPS for next quarter?+
The consensus estimate is $0.76 per share (range $0.64 – $0.87) across 6 analysts. Full-year EPS is projected at $2.88, rising to $3.65 the following year.
How much revenue is Pacira BioSciences, Inc. expected to report next quarter?+
Consensus revenue is $190.6M (range $188.8M – $192.5M). Full-year revenue is projected at $767.8M, growing to $831.3M next year.
Have analysts been upgrading or downgrading PCRX lately?+
As of Jul, 3 of 5 firms rate PCRX a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PCRX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
